Boothbay Fund Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Boothbay Fund Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-24,144	Closed	-$92K	–	1192
2020 Q1	$92K	Sell	24,144 -10,000	-29%	-$43.1K	0.01%	734
2019 Q4	$174K	Sell	34,144 -103,649	-75%	-$548K	0.02%	725
2019 Q3	$697K	Buy	137,793 +66,319	+93%	+$331K	0.06%	389
2019 Q2	$441K	Buy	+71,474	New	+$345K	0.04%	446
2016 Q2	–	Sell	-12,540	Closed	-$55K	–	627
2016 Q1	$55K	Buy	+12,540	New	+$55.8K	0.04%	278

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Boothbay Fund Management's PGNX Position: Q2 2020 in Review

Boothbay Fund Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 24,144 shares — an estimated $92K sold.

Boothbay Fund Management first reported a position in PGNX in Q1 2016 and held it in 5 quarters. The position peaked at $697K in Q3 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Boothbay Fund Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Boothbay Fund Management sold 24,144 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $92K.
Boothbay Fund Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2016 and held it in 5 quarters.
Boothbay Fund Management's Progenics Pharmaceuticals Inc position peaked at $697K in Q3 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Boothbay Fund Management's 13F filing for Q2 2020, filed 14 Aug 2020.